文献速递自身炎症与 IgG4 相关病

早期启动卡那奴单抗与Still病长期缓解及单周期病程相关:AIDA网络注册研究

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-20

基于国际AIDA网络注册的190例Still病患者,比较发病3个月内与之后启动卡那奴单抗的结局。早期启动组激素减量更快,因长期缓解停药的比例更高(OR 4.83),单周期病程发生率49% vs 8%。结论提示早期卡那奴单抗与长期缓解和单周期病程相关。

要点

  • 发病3个月内启动卡那奴单抗与因长期缓解停药独立相关(OR 4.83)。
  • 早期启动组单周期病程发生率为49%,显著高于晚期启动组的8%。
  • 早期启动组激素减量更快:3个月减50% vs 6%,6个月减75% vs 32%。

核心结论

  • 早期启动卡那奴单抗与Still病患者因长期缓解而停药相关,并似乎与更高的单周期病程频率相关。

研究设计与样本

  • 基于国际AIDA网络Still病注册队列,将接受卡那奴单抗治疗的患者按发病至启动时间分为≤3个月组(35例)与>3个月组(155例)进行比较。

主要发现

  • 共纳入190例患者,35例(19%)在发病3个月内启动卡那奴单抗,155例(82%)在之后启动。
  • 激素减量方面,3个月时减量≥50%的比例为早期组vs晚期组50% vs 6%(p=0.0001),6个月时减量≥75%的比例为75% vs 32%(p=0.004)。
  • logistic回归显示,发病3个月内启动卡那奴单抗与因长期缓解停药显著相关(OR 4.83,95%CI 1.08-23.19;p=0.04)。
  • 单周期病程发生于49%的早期启动患者 vs 8%的晚期启动患者(p<0.0001)。
  • 与慢性关节型(RRR 4.43,95%CI 1.12-17.60;p=0.034)和多周期型(RRR 8.97,95%CI 1.29-62.3;p=0.03)相比,发病3个月内启动卡那奴单抗与单周期病程显著相关。

临床怎么用

  • 对于Still病患者,在发病3个月内启动卡那奴单抗可能有助于更快减少激素用量、提高长期缓解停药概率并增加单周期病程机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether early canakinumab initiation may provide treatment advantages in Still's disease (SD) patients, particularly in terms of therapy discontinuation due to long-term disease remission, glucocorticoid sparing effect, and increase in the frequency of monocyclic disease course rather than a polycyclic or chronic articular pattern. METHODS: SD patients treated with canakinumab were grouped according to time between disease onset and canakinumab initiation (≤3 months vs. >3 months). Patients were enrolled from the international AutoInflammatory Disease Alliance (AIDA) Network registry for SD. RESULTS: Overall, 190 patients were enrolled, 35 (19%) treated with canakinumab within three months from SD onset and 155 (82%) starting canakinumab later. Glucocorticoids use decreased more rapidly in patients receiving canakinumab within 3 months from SD onset than among patients treated later, with reductions of 50% vs 6% at month 3 (p=0.0001), and 75% vs 32% at month 6 (p=0.004). In logistic regression analysis, canakinumab initiation within 3 months from disease onset was significantly associated with treatment discontinuation due to long-term remission (OR 4.83, 95% CI 1.08-23.19; p=0.04). A monocyclic course occurred in 49% of patients starting canakinumab ≤3 months versus 8% starting later (p<0.0001). Starting canakinumab within 3 months from disease onset was significantly associated with a monocyclic disease course compared with the chronic-articular (RRR 4.43, 95% CI 1.12-17.60; p=0.034) and polycyclic courses (RRR 8.97, 95% CI 1.29-62.3; p=0.03). CONCLUSIONS: Early canakinumab initiation is associated with treatment discontinuation due to long-term remission and appears linked to a greater frequency of a monocyclic disease course.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Vitale A, Caggiano V, Sbalchiero J, et al. Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry. Semin Arthritis Rheum. 2026. PMID: 42364377. doi:10.1016/j.semarthrit.2026.153030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。